New Lipid Nanoparticle Platform Delivers mRNA to the Brain Through the Blood-Brain Barrier | Newswise

New Lipid Nanoparticle Platform Delivers mRNA to the Brain Through the Blood-Brain Barrier | Newswise

Newswise — New York, NY [February 17, 2025]—Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier. The findings, in mouse models…

Read More
‘Gated’ CAR T-Cells Are Effective Against AML—With Less Toxicity | Newswise

‘Gated’ CAR T-Cells Are Effective Against AML—With Less Toxicity | Newswise

Newswise — Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for children with B-cell acute lymphoblastic leukemia (ALL). But unfortunately, CAR T-cells have been far less effective for another blood cancer: acute myeloid leukemia (AML). Now, a new study led by Babak Moghimi, MD, at Children’s Hospital Los Angeles has…

Read More
Tasso and ARUP Laboratories Announce Partnership, Combined Offering for Decentralized Clinical Research Biomarker Testing | Newswise

Tasso and ARUP Laboratories Announce Partnership, Combined Offering for Decentralized Clinical Research Biomarker Testing | Newswise

Newswise — SEATTLE and SALT LAKE CITY, Feb. 3, 2025  — Tasso Inc., the leading provider of patient-centric, clinical grade blood collection solutions, and ARUP Laboratories, the largest nonprofit clinical and academic reference laboratory in the United States, today announced that they have entered into a partnership to develop and operationalize high-quality, at-home, blood testing…

Read More
Small Molecules to Treat Pediatric Cancers | Newswise

Small Molecules to Treat Pediatric Cancers | Newswise

Newswise — Targeted therapies for high-risk leukemia in children have yet to be developed, but scientists at Université de Montréal and its affiliated Institute for Research in Immunology and Cancer are working on large-scale drug discovery project to get there. In the laboratory run by Brian Wilhelm, UdeM doctoral student in cancer genomics Safia Safa-Tahar-Henni…

Read More
Could Fecal Microbiota Transplantation Help Patients Heal After Stem Cell Transplantation?   | Newswise

Could Fecal Microbiota Transplantation Help Patients Heal After Stem Cell Transplantation? | Newswise

Newswise — SEATTLE — Jan. 28, 2025 — A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood cancers. The study, published Jan. 25 in Nature Communications, is part of a phase 2 clinical trial led by…

Read More
Small Molecules to Treat Pediatric Cancers | Newswise

Hypertensive Urgency: Teaching Improved Care for an Acute Form of High Blood Pressure | Newswise

BYLINE: Eva Cornman Newswise — Nearly half of all adults in the United States are living with hypertension, or blood pressure above 130/80 mmHg. Despite its prevalence, managing high blood pressure remains a major challenge in healthcare settings. Hypertension management can be challenging for a number of reasons, explains Benjamin Gallagher, MD, a hypertension specialist and…

Read More
Society of Hematologic Oncology (SOHO) Launches SOHO Insider: Your Premier Hematologic Oncology News Source | Newswise

Society of Hematologic Oncology (SOHO) Launches SOHO Insider: Your Premier Hematologic Oncology News Source | Newswise

Newswise — LOS ANGELES, Jan. 7, 2025 /PRNewswire/ — The Society of Hematologic Oncology (SOHO) is proud to announce the launch of SOHO Insider (www.sohoinsider.com), a digital and print publication that features the most cutting-edge news, expert opinions, and in-depth analysis on the latest developments in hematologic oncology. SOHO Insider will serve as the go-to resource for clinicians, researchers, healthcare…

Read More
Small Molecules to Treat Pediatric Cancers | Newswise

New Trial Tests Cell Therapy for Neonates With CMV  | Newswise

Newswise — A first-of-its-kind clinical trial at Children’s Hospital Los Angeles is investigating a novel protocol for neonates with congenital cytomegalovirus (CMV): virus-specific T-cell therapy. The phase 2 randomized trial represents a potentially groundbreaking approach to treating congenital CMV in newborns—which can lead to hearing loss and deafness, developmental delays, vision loss, and more. Antiviral…

Read More